Folgen
-
Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
-
Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
-
Fehlende Folgen?
-
David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
-
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
-
JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
-
Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.
-
Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.
-
Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology
-
Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
-
Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism
-
Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.
-
Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
-
Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.
-
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
-
前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
-
膀胱がんの最新の話題〜周術期薬物療法とADC〜
-
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
-
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
-
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
-
Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.
- Mehr anzeigen
